Skip to main content

Table 1 Baseline characteristics of both groups

From: Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma

  cTACE (n = 174) DEB TACE (n = 76)  
  n % n % p
Patient demographics      
Sex      0.17
Male 144 82.8 68 89.5  
Female 30 17.2 8 10.5  
Age (years)      0.04
<60 46 26.4 11 14.5  
≥60 128 73.6 65 85.5  
Etiology of liver cirrhosisa      
Alcohol      0.15
Yes 86 49.4 30 39.5  
No 88 50.6 46 60.5  
HCV      0.91
Yes 47 27.0 20 26.3  
No 127 73.0 56 73.7  
HBV      0.21
Yes 14 8.0 10 13.2  
No 160 92.0 66 86.8  
NASH      0.29
Yes 10 5.7 2 2.6  
No 164 94.3 74 97.4  
Cryptogen      0.01
Yes 5 2.9 8 10.5  
No 169 97.1 68 89.5  
Prior curative treatment      0.01
Yes 17 9.8 17 22.4  
No 157 90.2 59 77.6  
Liver function/patient status      
BCLC      0.21
A 30 17.2 8 10.5  
B 59 33.9 34 44.7  
C 77 44.3 30 39.5  
D 8 4.6 4 5.3  
ECOG      0.44
0 110 63.2 53 69.7  
1 61 35.1 20 26.3  
2 2 1.1 2 2.6  
3 1 0.6 1 1.3  
Portal invasion      0.25
Yes 36 20.7 11 14.5  
No 138 79.3 65 85.5  
Metastasis      0.66
Yes 5 2.9 3 3.9  
No 169 97.1 73 96.1  
Child      0.48
A 103 59.2 51 67.1  
B 64 36.8 22 28.9  
C 7 4.0 3 3.9  
Bilirubin (mg/dl)      0.40
<2 136 78.2 64 84.2  
2-3 24 13.8 9 11.8  
>3 14 8.0 3 3.9  
Albumin (mg/dl)      0.54
>3.5 76 43.7 29 38.2  
2.8-3.5 67 38.5 35 46.1  
<2.8 31 17.8 12 15.8  
INR      0.35
<1.7 172 98.9 76 100.0  
1.7-2.3 2 1.1 0 0.0  
>2.3 0 0.0 0 0.0  
Ascites      0.55
None 118 67.8 61 80.3  
Mild 38 21.8 11 14.5  
Moderate to severe 18 10.3 4 5.3  
Hepatic encephalopathy      0.26
None 173 99.4 75 98.7  
Grade I-II 1 0.6 1 1.3  
Grade III-IV 0 0.0 0 0.0  
Tumor characteristics      
Tumor grading      0.08
G1 80 46.0 34 44.7  
G2 82 47.1 30 39.5  
G3 12 6.9 12 15.8  
Milan criteria      0.13
In 47 27.0 14 18.4  
Out 127 73.0 62 81.6  
SLD (cm)      0.93
<3 19 10.9 8 10.5  
≥3 155 89.1 68 89.5  
  1. HBV hepatitis B virus, HCV hepatitis C virus, NASH nonalcoholic steatohepatitis, BCLC barcelona clinic liver cancer classification, ECOG eastern cooperative oncology group, INR international normalized ratio, SLD sum of the longest diameter
  2. a5 patients with HBV/HCV co-infection